Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale

  title={Adopting a Patient-Centered Approach to Primary Outcome Analysis of Acute Stroke Trials Using a Utility-Weighted Modified Rankin Scale},
  author={Napasri N. Chaisinanunkul and Opeolu M. Adeoye and Roger J. Lewis and James Charles Grotta and Joseph P. Broderick and Tudor G. Jovin and Raul G. Nogueira and Jordan J. Elm and Todd L Graves and Scott M. Berry and Kennedy R. Lees and Andrew David Barreto and Jeffrey L. Saver and Anthony J. Furlan and Blaise Baxter and Helmi L Lutsep and Marc Rib{\'o} and Olav Jansen and Rishi Gupta and Vitor M Pereira},
Background and Purpose— Although the modified Rankin Scale (mRS) is the most commonly used primary end point in acute stroke trials, its power is limited when analyzed in dichotomized fashion and its indication of effect size challenging to interpret when analyzed ordinally. Weighting the 7 Rankin levels by utilities may improve scale interpretability while preserving statistical power. Methods— A utility-weighted mRS (UW-mRS) was derived by averaging values from time-tradeoff (patient centered… 

Figures and Tables from this paper

Utility-Weighted Modified Rankin Scale as Primary Outcome in Stroke Trials
The UW-mRS as primary outcome does not capture individual variation in utility values and may reduce the statistical power of a randomized trial.
Utility-weighted modified Rankin Scale: Still too crude to be a truly patient-centric primary outcome measure?
The high variability in utility values between and within mRS categories, over time post-stroke, and using different derivation methods is not adequately reflected in the UW-mRS.
Improving Visualization Methods of Utility-Weighted Disability Outcomes for Stroke Trials
Utility Staircase displays are an efficient graphical format for conveying utility weighted–modified Rankin Scale primary endpoint results of acute stroke trials, and choropleth-stacked-bar-charts a good alternative.
Utility-Weighted Modified Rankin Scale Scores for the Assessment of Stroke Outcome
Despite variable differences with mRS scores, the UW-mRS provides efficiency gains as a smaller sample size is required to detect a treatment effect in acute stroke trials through use of continuous scores.
Ordinal vs dichotomous analyses of modified Rankin Scale, 5-year outcome, and cost of stroke
The ordinal form of the 3-month mRS relates better to long-term outcomes and costs in survivors of ischemic stroke than either dichotomy, and favors using ordinal approaches in trials analyzing the mRS.
Comparison of 3-Month Stroke Disability and Quality of Life across Modified Rankin Scale Categories
While significant differences in BI were observed across mRS categories, QoL in the mRS 2 and 3 categories was similar, and mRS 0-3, rather than 0-2, should be considered a good outcome category in moderate to severe ischemic stroke.
National Institutes of Health Stroke Scale
The NIHSS within 1 week satisfies the requirements for a surrogate end point and may be used as a primary outcome measure in trials of acute treatment for ischemic stroke, particularly in phase II(b) trials.
Standardized Nomenclature for Modified Rankin Scale Global Disability Outcomes
This statement advances recommended rubrics, developed by the Stroke Therapy Academic Industry Roundtable collaboration using an iterative, mixed-methods process, to enable the modified Rankin Scale to meet robust contemporary scale standards.


Quantifying the Value of Stroke Disability Outcomes: WHO Global Burden of Disease Project Disability Weights for Each Level of the Modified Rankin Scale
Formal DW assignment confirms that the modified Rankin Scale is an ordered but unequally spaced scale, and permits direct comparison of each poststroke outcome state with the outcomes of hundreds of other diseases in the WHO-GBDP and the expression of stroke burden in different populations by using the uniform metric of disability-adjusted life-years lost.
Treatment effects for which shift or binary analyses are advantageous in acute stroke trials
The pattern of treatment effect of the intervention determines whether shift analysis or simple dichotomized analysis will be more efficient, and shift analysis is especially advantageous when treatments confer a relatively uniform, mild benefit to patients over a wide range of stroke severities.
Statistical Analysis of the Primary Outcome in Acute Stroke Trials
Because there is no best approach that will work for all acute stroke trials, it is vital that studies are designed with a full understanding of the type of patients to be enrolled, the potential mechanism by which the intervention works, and an understanding of what the intervention will cost if implemented in clinical practice.
Optimal End Points for Acute Stroke Therapy Trials: Best Ways to Measure Treatment Effects of Drugs and Devices
Stroke trial power and interpretation can be substantially enhanced by adherence to the principles delineated in this review, especially when compared with fixed dichotomous approaches.
Mapping the Modified Rankin Scale (mRS) Measurement into the Generic EuroQol (EQ-5D) Health Outcome
An algorithm is constructed to translate the modified Rankin scale (mRS) into EQ-5D utility values that can be used with different country-specific tariff valuations and should not replace prospective collection of utility data.
Patient Preferences for Stroke Outcomes
Data from this study are useful in interpreting studies that report stroke and death, in designing new studies that measure stroke in at-risk populations, and in helping patients reach treatment decisions about therapies designed to prevent strokes.
A Longitudinal Comparison of 5 Preference-Weighted Health State Classification Systems in Persons with Intervertebral Disk Herniation
This research supports the validity of all systems for measuring change in persons with IDH, without finding a clearly superior system.
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Important differences in EQ-5D utility and VAS scores were similar for all cancers and lung cancer, with the lower end of the range of estimates closer to the MID, i.e. 0.08 for UK-index scores, 0.06 for US- index scores, and 0.07 for VAS Scores.
The SOAR Stroke Score Predicts Inpatient and 7-Day Mortality in Acute Stroke
A simple score based on 4 easily obtainable variables at the point of care may potentially help predict early stroke mortality.
Tissue plasminogen activator for acute ischemic stroke.
  • Koroshetz Wj
  • Medicine, Psychology
    The New England journal of medicine
  • 1995
Despite an increased incidence of symptomatic intracerebral hemorrhage, treatment with intravenous t-PA within three hours of the onset of ischemic stroke improved clinical outcome at three months.